Luoxis Establishes Study Collaborations with Two Research Centers in Oxidative
Research collaborations advance company goal of incorporating RedoxSYS™
oxidation-reduction potential platform into clinical practice and broaden the
scope of applications in the critical care setting
GREENWOOD VILLAGE, Colo., Jan. 6, 2014
GREENWOOD VILLAGE, Colo., Jan. 6, 2014 /PRNewswire/ -- Ampio Pharmaceuticals,
Inc. (NYSE MKT: AMPE) today announced that subsidiary Luoxis has entered into
research agreements with Western Galilee Medical Center (Nahariya, Israel) and
the University of Thessaly (Larissa, Greece). These two leading oxidative
stress research groups will utilize Luoxis' proprietary RedoxSYS
oxidation-reduction potential (ORP) diagnostic system to study oxidative
stress markers across hypertension, hemodialysis, sepsis, and physical
Western Galilee Medical Center, based in Nahariya, Israel, is a leading
institution in the study of oxidative stress. Dr. Shifra Sela and Dr. Batya
Kristal will serve as the principle investigators studying oxidation-reduction
potential in hypertension and hemodialysis. Both researchers have studied
oxidative stress for over 20 years, and their work has been extensively
The University of Thessaly, comprising faculties of Medicine, Biochemistry and
Biotechnology in Larissa, Greece, is an established institution supported by
University Hospital of Larissa and focused on patient care and research,
including the study of oxidative stress in critical conditions. Dr. Maria
Karapetsa, Dr. Epaminondas Zakynthinos, Dr. Dimitrios Kouretas, and Dr.
Dimitrios Stagos will serve as the principle investigators studying
oxidation-reduction potential in sepsis and physical exertion. All researchers
have multiple publications to their credit.
"We are pleased to be partnering with Western Galilee Medical Center and the
University of Thessaly on these important research projects," said Josh
Disbrow, Chief Executive Officer of Luoxis. "Luoxis and these prominent
research teams share a strong interest in advancing the study of oxidative
stress, and we believe incorporating oxidation-reduction potential
measurements into current diagnostic practice will significantly advance
assessment of human oxidative stress in prevalent and challenging patient
Both research centers, in collaboration with Dr. David Bar-Or, Ampio and
Luoxis Chief Scientific Officer, expect to publish the results of their
research in peer-reviewed publications following completion of the studies.
About the RedoxSYS Diagnostic System
The RedoxSYS diagnostic system is a patented diagnostic device with
accompanying disposable sensors that rapidly measures and reports unique
oxidative stress parameters by analyzing a single drop of a biologic specimen.
Prior to the development of the RedoxSYS diagnostic system, oxidative stress
measurement was incomplete, time consuming and impractical in a clinical
setting. The RedoxSYS diagnostic system enables robust and rapid assessment of
oxidative stress via measurement of oxidation-reduction potential (ORP) in the
clinical setting. ORP is a homeostatic parameter capturing the balance of
oxidants and reductants in a biologic system, a complete measure of oxidative
stress. Multiple clinical trials have been completed using the RedoxSYS
diagnostic system and have demonstrated the predictive value of ORP across
Luoxis is a biotechnology company focused on the development and global
commercialization of the RedoxSYS diagnostic system. The RedoxSYS diagnostic
system is comprised of a portable analyzer and disposable sensors that rapidly
measure the level of oxidative stress and antioxidant reserves in biologic
specimens via assessment of oxidation-reduction potential (ORP). ORP has been
shown to be an important measure in both critical and chronic illnesses and is
a novel marker of patient morbidity across a wide range of conditions. There
are numerous clinical indications for this homeostatic parameter for which
there is no currently available test. Luoxis is a majority-owned subsidiary of
Ampio Pharmaceuticals, Inc.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company
primarily focused on the development of therapies to treat prevalent
inflammatory conditions for which there are limited treatment options. We are
developing compounds that decrease inflammation by (i) inhibiting specific
pro-inflammatory compounds by affecting specific pathways at the protein
expression and at the transcription level; (ii) activating specific
phosphatase or depletion of the available phosphate needed for the
inflammation process; and (iii) decreasing vascular permeability.
Forward Looking Statement
Ampio's statements in this press release that are not historical fact and that
relate to future plans or events are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by use of words such as
"believe," "expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include risks associated with clinical trials,
expected results, regulatory approvals, and changes in business conditions and
similar events. The risks and uncertainties involved include those detailed
from time to time in Ampio's filings with the Securities and Exchange
Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports
on Form 10-Q.
Director of Investor Relations
Ampio Pharmaceuticals, Inc.
Direct: (720) 437-6530
SOURCE Ampio Pharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.